NCT03002220 - Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2016

Primary Completion Date

May 6, 2020

Study Completion Date

June 9, 2021

Conditions

Prostate Cancer

Interventions

DRUG

radium-223

Radium-223 at a dose of 55 kBq

Trial Locations (6)

MedSIR Investigative site, Barcelona

MedSIR Investigative site, Cáceres

MedSIR Investigative site, Córdoba

MedSIR Investigative site, Lugo

MedSIR Investigative site, Madrid

MedSIR investigative site, Palma de Mallorca